Celgene Corporation
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$40Mgeneral payments (2019-2025)
$2.8Mresearch payments (2019-2025)
45,335clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Zeposia $2.4M associated (2023-2025)
- Reblozyl $1.0M associated (2023-2025)
- Pomalyst $275K associated (2023-2025)
- Opdualag $101K associated (2023-2025)
- Onureg $69K associated (2023-2025)
- Opdivo $41K associated (2023-2025)
- Breyanzi $34K associated (2023-2025)
- Sotyktu $17K associated (2023-2025)
- Abecma $15K associated (2023-2025)
- Camzyos $12K associated (2023-2025)
- Orencia $3,897 associated (2023-2025)
- Eliquis $2,496 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Julia Haller | Philadelphia, PA | Ophthalmology | $551,081.79 |
| Michael Friedman | Pasadena, CA | $549,925.24 | |
| Bart Scott | Seattle, WA | Medical Oncology | $204,259.63 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $203,651.94 |
| Thomas Leist | Philadelphia, PA | Neurology (Psychiatry & Neurology) | $195,743.22 |
| Thomas Leblanc | Durham, NC | Medical Oncology | $194,954.44 |
| Ralph Boccia | Bethesda, MD | Hematology & Oncology | $175,063.64 |
| Suzanne Fanning | Greenville, SC | Hematology & Oncology | $154,525.85 |
| Bhupendra Khatri | Milwaukee, WI | Neurology (Psychiatry & Neurology) | $149,752.22 |
| Joshua Richter | New York, NY | Medical Oncology | $149,530.39 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.